National Library of Medicine; Notice of Partially Closed Meeting

2026-06501 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.

2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration

The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!

2026-05957 — Center for Scientific Review; Notice of Closed Meetings

The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.

2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.

2026-05673 — Center for Scientific Review; Notice of Closed Meetings

The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.

2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)

The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!

Previous: 2026-01938 — Center for Scientific Review; Notice of Closed Meetings

The NIH’s Center for Scientific Review is holding several closed virtual meetings in March 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.

Next: 2026-01940 — Bulk Manufacturer of Controlled Substances Application: Promega Corporation

Promega Corporation wants to make large amounts of psilocybin and psilocyn, two controlled substances, to sell as ingredients for medicines. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 3, 2026. This move could boost medicine development but also means Promega will handle some powerful substances under strict rules.